A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Published

Journal Article

PURPOSE: The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. METHODS: PZA was administered intravenously over 3 h every 3 weeks. A dose of 760 mg/m(2) was given to the first 11 patients and was reduced to 560 mg/m(2) for subsequent patients. The dose reduction was undertaken because of unexpected severe neutropenia among the initial patients. RESULTS: Among 24 evaluable patients, 21 of whom had prior chemotherapy, there was one, brief, complete response (4.2%) and no partial responses. The major toxicity was neutropenia. CONCLUSION: PZA at the dose and schedule employed, has insignificant activity in this population.

Full Text

Cited Authors

  • Plaxe, SC; Blessing, JA; Olt, G; Husseinzadah, N; Lentz, SS; DeGeest, K; Valea, FA

Published Date

  • August 2002

Published In

Volume / Issue

  • 50 / 2

Start / End Page

  • 151 - 154

PubMed ID

  • 12172981

Pubmed Central ID

  • 12172981

Electronic International Standard Serial Number (EISSN)

  • 1432-0843

International Standard Serial Number (ISSN)

  • 0344-5704

Digital Object Identifier (DOI)

  • 10.1007/s00280-002-0470-2

Language

  • eng